Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New device aims to heal stubborn diabetic foot sores

NCT ID NCT06003400

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early study tests a device called FITT on 20 people with hard-to-heal diabetic foot ulcers. The device combines several treatments to try to shrink the wound and ease pain. Researchers are checking if it is safe and if it improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FITT device (a combination therapy device for wound healing)
What this could lead to
If it works, this device could offer a new way to help heal stubborn diabetic foot ulcers and reduce pain.
What could go wrong
This is a very early, small trial with only 20 people. The device's exact method is secret, and it may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females 18-80 years old * Chronic Diabetes Mellitus type 1 and type 2 diagnosed at least 3 years before the screening * Have a single non-infected diabetic hard-to-heal wound (ulcers/foot ulcers) ≤ 0.8-40 cm2 wound area at start of treatment, for period of at least for 3 months. * Wagner classification stage 1 or 2 or post-debridement stage 3. * At least moderate blood perfusion into the affected limb as defined by Ankle Brachial Index (ABI) ≥0.65 * Stable diabetic drugs 4 weeks before Screening * Be available for the entire study period, and be able and willing to adhere to protocol requirements * Provide written informed consent prior to admission into the study Exclusion Criteria: * Have a glycosylated hemoglobin (HbA1c) \> 10.5% * Have more than one wound * Have a body mass index (BMI) \> 40 kg/m2 * Have visible bone exposure at wound site * Anemia (Hemoglobin \< 9 g/dL) or White Blood Cells count \> 11,000/μL or Platelets count \< 100,000/μL or liver function tests \> 3 times upper normal lab values or Creatinine \> 3 mg/dL; any indication of malnourishment (Albumin \< 3 g/dL); INR\>2 or any other clinically significant blood and urinalysis tests per the physician's discretion * Patients with unstable hypertension * Have any clinically significant chronic or acute illness during the 4 weeks prior to admission into the study, except diabetes type 1 or 2 or during screening period * Females who are pregnant, lactating, of child-bearing potential, or post-menopausal for less than 2 years, not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test * Participation in a clinical study or use of an investigational drug within 30 days prior to admission to this study * Patients with active Gangrenous foot ulcers * Active osteomyelitis (Have any signs of infection in the wound (which could be linked to raised body temperature), abscess, cellulitis, necrosis, erythema, mild drainage or known osteomyelitis) * Patients with uncontrolled hyperthyroidism * Patients with history of collagen diseases * Patients with known allergy to ozone * Anxiety, Depression, history of Mental illness or patient under Guardian * Any medical condition for which the investigator deems the subject unable to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic foot ulcer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Diabetic Foot

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hilel Yafe Medical Center

    Hadera, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.